<scp>PD</scp>‐1 as a potential target in cancer therapy
David F. McDermott(Beth Israel Deaconess Medical Center), Michael B. Atkins(Georgetown University)
Cited by 409
Related Papers
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
|Nature Communications|2016|708
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
|Journal of Clinical Oncology|2022|427
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
|Journal for ImmunoTherapy of Cancer|2023|30